Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
SAN DIEGO, April 28, 2011 /PRNewswire/ — Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced that additional data from the DIFICID(TM) Phase 3 trials will be presented at the following medical meetings:
Digestive Disease Week (DDW), McCormick Place, Chicago, IL May 7-10, 2011 Poster Presentation Information: Risk of Recurrence and Time to Recurrence Following Title: Treatment of Clostridium difficile Infection: Patient Characteristics and the Differential Effect of Fidaxomicin vs. Vancomycin Presenter: Kathleen M. Mullane, D.O. Date: Saturday, May 7, 2011 Time: 12:00 p.m. to 2:00 p.m. Central Time Location: Poster Session Hall A (MCP) Intestinal Disorders: Prebiotics, Probiotics and Session: Pathogens Program #: Sa1981 Poster Presentation Information: High Fecal and Low Plasma Levels of Fidaxomicin and Title: Metabolite OP-1118 in Patients with C. difficile infection: Combined Results of Two Phase 3 Trials Presenter: Pamela S. Sears, Ph.D. Date: Monday, May 9, 2011 Time: 12:00 p.m. to 2:00 p.m. Central Time Location: Poster Session Hall A (MCP) Session: Randomized Controlled Clinical Trials Program #: Mo1160 European Congress of Clinical Microbiology and Infectious Diseases and International Congress of Chemotherapy, Milano Convention Center, Milan, Italy May 7-10, 2011 Oral Presentation Information: Immunosuppression and the Risk of Death, Cure Rates Title: and Disease Recurrence Among Patients with Clostridium difficile Infection Presenter: Yoav Golan, M.D., M.S. Date: Tuesday, May 10, 2011 Time: 10:36 a.m. to 10:48 a.m. Central European Time Location: Lecture Hall Brown 1 Oral Session: C. difficile News Presentation #: O504 Poster Presentation Information: Clostridium difficile Recurrence, Alcohol Title: Consumption, and the Effect of Fidaxomicin vs. Vancomycin Presenter: Yoav Golan, M.D., M.S. Date: Tuesday, May 10, 2011 Time: 12:30 p.m. to 1:30 p.m. Central European Time Location: Poster Area Hall 5 Poster Topic 99: Clostridium difficile Poster ID#: P1968 2011 Annual Scientific Meeting of the American Geriatrics Society (AGS), The Gaylord National Hotel, National Harbor, Maryland May 11-14, 2011 Poster Presentation Information: Effect of Advancing Age on Outcomes of Therapy for Title: Clostridium difficile Infection Presenter: Thomas J. Louie, M.D. Date: Thursday, May 12, 2011 Time: 4:30 p.m. to 6:00 p.m. Eastern Time Session: Presidential Poster Session B Location: Exhibit Hall Poster ID#: B126
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has two anti-infective product candidates in development, DIFICID(TM) (fidaxomicin) and Pruvel(TM) (prulifloxacin). DIFICID is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company’s request for six-month Priority Review of Optimer’s NDA for DIFICID, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for DIFICID. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
Optimer Pharmaceuticals, Inc.
Christina Donaghy, Corporate Communications Manager
John D. Prunty, Chief Financial Officer & VP Finance
Jason I. Spark, Senior Vice President
SOURCE Optimer Pharmaceuticals, Inc.